Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282510 · ClinicalTrials.gov registry record · Phase 4
Nasal Antisepsis for C. Auris Prevention
A Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic, sponsored by Mary K Hayden.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06282510 is a Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic that is actively recruiting participants, run by Mary K Hayden. The registered enrollment target is 120 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT06282510, a Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic, is actively recruiting participants, sponsored by Mary K Hayden.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Conditions Studied
Interventions
- DRUG Povidone Iodine Topical
Study Locations (3)
Illinois
- Rush University Medical Center - Chicago
- RML Specialty Hospital - Chicago
- RML Specialty Hospital - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06282510
The ClinicalTrials.gov registry entry for NCT06282510 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mary K Hayden, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Candida Auris Infection appearing as the primary indexed condition, and to 1 intervention - of which Povidone Iodine Topical is the first listed.
NCT06282510 reports 3 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06282510 about?
NCT06282510 is a clinical study titled "Nasal Antisepsis for C. Auris Prevention". This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
What is the current status of trial NCT06282510?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-01-29. Estimated completion is 2028-12.
What conditions does trial NCT06282510 study?
This clinical trial studies the following conditions: Candida Auris Infection, Colonization, Asymptomatic.
What interventions are being tested in trial NCT06282510?
The interventions under investigation include: Povidone Iodine Topical (DRUG).
Who is sponsoring clinical trial NCT06282510?
This trial is sponsored by Mary K Hayden, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282510 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.